Clinical trials invest considerable effort in helping people understand a study before they join. Maintaining that understanding over the months or years that follow is a different challenge.
Participant communication has become considerably more sophisticated.
Many trials now use patient-centred recruitment, lay-friendly consent materials, digital engagement tools and structured communication throughout participation. CROs and patient organisations have played an important role in that development.
So the question is no longer whether communication continues after consent.
It is whether understanding does.
Participants do not necessarily experience a trial as the neat sequence shown in a communication plan. They enter studies at different times, may follow different treatment pathways and can experience delays, rescheduled visits or extended follow-up.
Someone may understand a procedure clearly during consent and encounter it six months later with only a vague recollection of why it matters. A change in treatment or study phase may raise questions that did not exist at enrolment.
Participant contact is not necessarily participant understanding.
Consent sets a high standard
The EU Clinical Trials Regulation requires information provided for informed consent to be comprehensive, concise, clear, relevant and understandable to a layperson.¹ It also places emphasis on establishing that the participant has understood the information provided during the consent process.
Considerable effort rightly goes into translating a complex protocol into something a person considering participation can understand.
But once the study is under way, time begins to work against that initial understanding.
Participants are living their lives alongside the trial (working, caring for families and, in many cases, managing the condition that brought them to the study). Long periods may separate visits or important study events. Information explained at enrolment may only become practically relevant months later.
Consent establishes understanding at one important moment. The participant journey needs to maintain it.
The communication plan and the participant journey are not the same thing
This is where CROs and patient organisations have particularly valuable insight.
They hear the questions participants actually ask. They see when information provided earlier is no longer enough, when complex medical or scientific information creates uncertainty, or when communications developed by different teams do not quite connect.
The answer is not necessarily more information.
Sometimes something explained during consent simply needs to return when it becomes relevant. A participant approaching a complex procedure may need a reminder of why it is happening. Someone entering a new study phase may need context around what has changed and what comes next.
The challenge is that these needs develop at participant level.
A communication plan can provide structure, but different participants may reach the same study events at different times and with different levels of knowledge, recall and experience.
That creates a different communication challenge: not simply providing information, but helping complex information remain useful throughout an individual participant journey.
Designing for understanding
Medical and scientific communicators already deal with a version of this problem every day. At later stages of the product lifecycle, we already have well-established processes for delivering complex drug information and adapting it for different audiences, contexts and information needs.
Complex information has to be prioritised, structured and expressed in language appropriate to the audience. Timing matters. Format matters. Context matters.
Clinical trial communication carries additional ethical, regulatory and study-specific responsibilities, but the underlying communication challenge is familiar so
Why can’t we apply some of the same principles earlier, during clinical development?
Research into participant preferences for receiving study findings shows that people value access to results while differing in their preferences for content, timing and format.²
Making information available is not necessarily the same as making it useful to the person receiving it.
For some trials, relatively little additional support may be needed. Others (particularly those involving long participation, complex procedures, different treatment pathways or demanding scientific concepts) may require more deliberate communication design across the participant journey.
Building understanding into study planning
Most sophisticated trials already include participant communication within study planning.
CROs are often well placed to identify these requirements early because they sit across protocol delivery, site operations and participant-facing activity.
The additional question is whether the likely complexity of maintaining understanding has been considered too.
Where complex protocol, medical or scientific information may need to be interpreted, adapted or revisited, it makes sense to identify that requirement early. Doing so gives sponsors and their CRO partners a better basis for deciding what communication expertise and resources should be included in the study budget.
It also reduces the likelihood that emerging communication needs are simply absorbed later by sites or teams whose primary responsibility lies elsewhere.
This does not mean assuming that more communication will improve retention or solve every participant challenge. Trial participation is influenced by many factors.
It means recognising that participant understanding itself can be designed for rather than simply assumed.
Regulation is reinforcing the principle
There is another reason this question is timely.
From 28 April 2026, the revised UK clinical trials framework strengthened requirements around research transparency.³ For trials submitted under the new framework, participants, or other relevant people, must be offered a summary of trial results in a form understandable to members of the public, subject to the applicable provisions.⁴
The EU Clinical Trials Regulation similarly requires a summary of clinical trial results written in terms understandable to laypersons.¹
Yet in April 2026, the Health Research Authority reported that only 52% of studies completed in 2023 had shared their results with participants or were in the process of doing so. Twenty-four per cent reported that they had not, while for another 24% the position was unknown because a final report had not been received.⁵
There is an interesting symmetry here.
At the beginning of a trial, considerable effort goes into helping someone understand what they are agreeing to.
At the end, regulation increasingly expects results to be returned in a form people can understand.
Between those points may sit months or years of procedures, visits, decisions and changing information needs.
What happens to understanding in between?
For CROs and patient organisations discussing participant strategy with sponsors, that leaves one useful question to put on the table:
We have budgeted for participant communication. Have we budgeted for participant understanding?
References
¹ European Parliament and Council of the European Union. Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use. Official Journal of the European Union. 27 May 2014.
https://eur-lex.europa.eu/eli/reg/2014/536/oj
² Cook S, Mayers S, Goggins K, Schlundt D, Bonnet K, Williams N, Alcendor D, Barkin S. Assessing research participant preferences for receiving study results. Journal of Clinical and Translational Science. 2020;4(3):243–249. doi:10.1017/cts.2019.427.
³ The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, SI 2025/538. The National Archives, legislation.gov.uk.
https://www.legislation.gov.uk/uksi/2025/538/pdfs/uksi_20250538_en.pdf
⁴ Health Research Authority. Offering to share a summary of results with participants. Updated 28 April 2026.
⁵ Health Research Authority. New research transparency data on UK clinical trials published. 21 April 2026.
